Cargando…
Antiviral Efficacy of Verdinexor In Vivo in Two Animal Models of Influenza A Virus Infection
Influenza A virus (IAV) causes seasonal epidemics of respiratory illness that can cause mild to severe illness and potentially death. Antiviral drugs are an important countermeasure against IAV; however, drug resistance has developed, thus new therapeutic approaches are being sought. Previously, we...
Autores principales: | Perwitasari, Olivia, Johnson, Scott, Yan, Xiuzhen, Register, Emery, Crabtree, Jackelyn, Gabbard, Jon, Howerth, Elizabeth, Shacham, Sharon, Carlson, Robert, Tamir, Sharon, Tripp, Ralph A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5125695/ https://www.ncbi.nlm.nih.gov/pubmed/27893810 http://dx.doi.org/10.1371/journal.pone.0167221 |
Ejemplares similares
-
In vitro toxicity and efficacy of verdinexor, an exportin 1 inhibitor, on opportunistic viruses affecting immunocompromised individuals
por: Widman, Douglas G., et al.
Publicado: (2018) -
Verdinexor Targeting of CRM1 is a Promising Therapeutic Approach against RSV and Influenza Viruses
por: Pickens, Jennifer A., et al.
Publicado: (2018) -
Identification of Host Kinase Genes Required for Influenza Virus Replication and the Regulatory Role of MicroRNAs
por: Bakre, Abhijeet, et al.
Publicado: (2013) -
Selinexor, a novel selective inhibitor of nuclear export, reduces SARS-CoV-2 infection and protects the respiratory system in vivo
por: Kashyap, Trinayan, et al.
Publicado: (2021) -
Targeting the pro-inflammatory factor CCL2 (MCP-1) with Bindarit for influenza A (H7N9) treatment
por: Wolf, Stefan, et al.
Publicado: (2017)